Correction: Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010 (JAMA Internal Medicine DOI:10.1001/jamainternmed.2014.4005);Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010

JAMA Internal Medicine

Volumn 174, Issue 10, 2014, Pages 1668-1673

  Bachhuber, Marcus A ^a,b   Saloner, Brendan ^b   Cunningham, Chinazo O ^c   Barry, Colleen L ^b,d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEDICAL CANNABIS; OPIATE; NARCOTIC ANALGESIC AGENT;

ARTICLE; CANNABIS USE; CONTROLLED STUDY; DEATH CERTIFICATE; DRUG FATALITY; DRUG OVERDOSE; HEALTH CARE POLICY; HUMAN; LAW; MULTICENTER STUDY (TOPIC); POPULATION RISK; TIME SERIES ANALYSIS; UNEMPLOYMENT; UNITED STATES; ADULT; AGED; DRUG LEGISLATION; FEMALE; MALE; MIDDLE AGED; MORTALITY; TRENDS;

ADULT; AGED; ANALGESICS, OPIOID; DRUG OVERDOSE; FEMALE; HUMANS; LEGISLATION, DRUG; MALE; MEDICAL MARIJUANA; MIDDLE AGED; MORTALITY; UNITED STATES;

EID: 84907990276     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2014.5823     Document Type: Erratum

References (42)

1. Gaskin DJ, Richard P. The economic costs of pain in the United States. J Pain. 2012;13(8):715-724.
2. Daubresse M, Chang HY, Yu Y, et al. Ambulatory diagnosis and treatment of nonmalignant pain in the United States, 2000-2010. Med Care. 2013;51 (10):870-878.
3. Centers for Disease Control and Prevention. Vital signs: overdoses of prescription opioid pain relievers-United States, 1999-2008. MMWR Morb Mortal Wkly Rep. 2011;60(43):1487-1492.
4. Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. JAMA. 2013; 309(7):657-659.
5. National Center for Injury Prevention and Control Division of Unintentional Injury Prevention. Policy impact: prescription painkiller overdoses. http://www.cdc.gov/homeandrecreationalsafety/pdf/policyimpact-prescriptionpainkillerod.pdf. Published November 2011. Accessed January 27, 2014.
6. National Conference of State Legislatures. State medicalmarijuana laws. http://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx. Published July 7, 2014. Accessed July 14, 2014.
7. Nevada Division of Public and Behavioral Health. Medical Marijuana Program Monthly Report. http://health.nv.gov/MedicalMarijuana-Reports.htm. January 2, 2014. Accessed January 27, 2014.
8. Licensing and Regulatory Affairs Bureau of Health Care Services. Michigan Medical Marihuana Act Statistical Report for Fiscal Year 2013. http://www.michigan.gov/documents/lara/BHCS-MMMP-MCL-333.26426i12345-Report-FINAL-12-4-13-441658-7.pdf. Published December 4, 2013. Accessed January 31, 2014.
9. Oregon Public Health Authority. Oregon Medical Marijuana Program statistics. https://public.health.oregon.gov/diseasesconditions/chronicdisease/medicalmarijuanaprogram/pages/data.aspx. Published January 1, 2014. Accessed January 31, 2014.
10. Montana Department of Public Health and Human Services. MontanaMarijuana Program Registry information. http://www.dphhs.mt.gov/marijuanaprogram/mmpregistryinformation.pdf. Published January 1, 2014. Accessed January 31, 2014.
11. Cerda M, Wall M, Keyes KM, Galea S, Hasin D. Medical marijuana laws in 50 states: investigating the relationship between state legalization of medical marijuana and marijuana use, abuse and dependence. Drug Alcohol Depend. 2012;120(1-3):22-27.
12. Fiellin LE, Tetrault JM, Becker WC, Fiellin DA, Hoff RA. Previous use of alcohol, cigarettes, and marijuana and subsequent abuse of prescription opioids in young adults. J Adolesc Health. 2013;52 (2):158-163.
13. Marijuana and Medicine: Assessing the Science Base. Washington, DC: National Academies Press; 1999.
14. Volkow ND, Baler RD, Compton WM, Weiss SR. Adverse health effects of marijuana use. N Engl J Med. 2014;370(23):2219-2227.
15. Centers for Disease Control and Prevention. CDC WONDER. National Vital Statistics System: 2010: Multiple Cause of Death Data. http://wonder.cdc.gov/mcd.html. AccessedMay 30, 2014.
16. National Alliance for Model State Drug Laws. Prescription Drug Monitoring Program dates of operation. March 2014. http://www.namsdl.org/library/1E4C142E-1372-636C-DD7711E627D4B892/. Accessed April 2, 2014.
17. Office for State Tribal Local and Territorial Support Centers for Disease Control and Prevention. Menu of state prescription drug identification laws. http://www.cdc.gov/phlp/docs/menu-pdil.pdf. Published June 30, 2013. Accessed January 27, 2014.
18. Office for State Tribal Local and Territorial Support Centers for Disease Control and Prevention. Menu of pain management clinic regulation. http://www.cdc.gov/phlp/docs/menu-pmcr.pdf. Published September 28, 2012. Accessed January 27, 2014.
19. US Bureau of Labor Statistics. Annual state unemployment. http://www.bls.gov/lau/home.htm. Accessed February 5, 2014.
20. Unick GJ, Rosenblum D, Mars S, Ciccarone D. Intertwined epidemics: national demographic trends in hospitalizations for heroin-and opioid-related overdoses, 1993-2009. PLoS One. 2013;8(2):e54496. doi:10.1371/journal.pone.0054496.
21. Khosla N, Juon HS, Kirk GD, Astemborski J, Mehta SH. Correlates of non-medical prescription drug use among a cohort of injection drug users in Baltimore City. Addict Behav. 2011;36(12):1282-1287.
22. Cicero TJ, Ellis MS, Surratt HL. Effect of abuse-deterrent formulation of Oxy Contin. N Engl J Med. 2012;367(2):187-189.
23. Peavy KM, Banta-Green CJ, Kingston S, Hanrahan M, Merrill JO, Coffin PO. "Hooked on" prescription-type opiates prior to using heroin: results from a survey of syringe exchange clients. J Psychoactive Drugs. 2012;44(3):259-265.
24. Angrist J, Pischke J. Mostly Harmless Econometrics: An Empiricist's Companion. Princeton, NJ: Princeton University Press; 2009.
25. Sidney S, Beck JE, Tekawa IS, Quesenberry CP, Friedman GD. Marijuana use and mortality. Am J Public Health. 1997;87(4):585-590.
26. Centers for Disease Control and Prevention. CDC grand rounds: prescription drug overdoses-a US epidemic. MMWR Morb Mortal Wkly Rep. 2012; 61(1):10-13.
27. Lynch ME, Campbell F. Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. Br J Clin Pharmacol. 2011;72(5):735-744.
28. Kumar RN, ChambersWA, Pertwee RG. Pharmacological actions and therapeutic uses of cannabis and cannabinoids. Anaesthesia. 2001;56 (11):1059-1068.
29. Abrams DI, Couey P, Shade SB, Kelly ME, Benowitz NL. Cannabinoid-opioid interaction in chronic pain. Clin Pharmacol Ther. 2011;90(6):844-851.
30. Lynch ME, Clark AJ. Cannabis reduces opioid dose in the treatment of chronic non-cancer pain. J Pain Symptom Manage. 2003;25(6):496-498.
31. Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med. 2010;152(2):85-92.
32. Bohnert AS, Valenstein M, BairMJ, et al. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA. 2011; 305(13):1315-1321.
33. Tanda G, Pontieri FE, Di Chiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common ?1 opioid receptor mechanism. Science. 1997;276(5321):2048-2050.
34. Scavone JL, Sterling RC, Van Bockstaele EJ. Cannabinoid and opioid interactions: implications for opiate dependence andwithdrawal. Neuroscience. 2013;248:637-654.
35. Ashton CH. Pharmacology and effects of cannabis: a brief review. Br J Psychiatry. 2001;178: 101-106.
36. Hermann D, Klages E, Welzel H, Mann K, Croissant B. Low efficacy of non-opioid drugs in opioid withdrawal symptoms. Addict Biol. 2005;10 (2):165-169.
37. Scavone JL, Sterling RC, Weinstein SP, Van Bockstaele EJ. Impact of cannabis use during stabilization onmethadone maintenance treatment. Am J Addict. 2013;22(4):344-351.
38. Lynskey MT, Heath AC, Bucholz KK, et al. Escalation of drug use in early-onset cannabis users vs co-twin controls. JAMA. 2003;289(4):427-433.
39. Yamaguchi K, Kandel DB. Patterns of drug use from adolescence to young adulthood, III: predictors of progression. Am J Public Health. 1984; 74(7):673-681.
40. Fergusson DM, Horwood LJ. Early onset cannabis use and psychosocial adjustment in young adults. Addiction. 1997;92(3):279-296.
41. Kandel DB. Does marijuana use cause the use of other drugs? JAMA. 2003;289(4):482-483.
42. Pacula RL, Sevigny EL. Marijuana liberalization policies: why we can't learn much from policy still in motion. J Policy Anal Manage. 2014;33(1):212-221.